Hugo Vanderstichele
Papers
1
Total Citations
62
H-Index
1
About
Hugo Vanderstichele is a leading figure in Alzheimer’s disease biomarker research, with a focus on the precise measurement of plasma β-amyloid (Aβ) for early diagnosis and longitudinal monitoring. His most cited work, the 2012 paper "Improved protocol for measurement of plasma β‐amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients" (62 citations), tackles a critical challenge in the field: the high interassay variability that has long hindered the reliable comparison of Aβ data across studies and centers. By developing and validating a standardized protocol, Vanderstichele enabled more consistent plasma Aβ measurements, paving the way for large-scale, multi-site analyses essential for clinical trials and biomarker validation. His contributions have directly supported the Alzheimer's Disease Neuroimaging Initiative (ADNI), one of the most influential research consortia in neurodegeneration. Through his methodological innovations, Vanderstichele has helped transform plasma Aβ from a promising but unreliable candidate into a more robust tool for tracking disease progression and evaluating therapeutic interventions, making his work indispensable for researchers seeking to translate biomarker science into clinical practice.
Research Focus
Key Achievements
Top Papers
- 1